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1  |  INTRODUC TION
Cancer- related cognitive impairment (CRCI) is one of the most feared 
adverse effects of cancer treatment (Ahles & Root, 2018). While oc-
currence rates vary based on the cognitive measures and impairment 
criteria used, CRCI occurs in 12%– 75% of patients receiving chemo-
therapy (CTX) (Loh et al., 2016). Older adults may be more vulnerable 
to CRCI (Ahles & Root, 2018; Lange, Rigal, et al., 2014) because the 
cancer itself and associated treatments may accelerate the neurode-
generative changes seen with aging (Freedman et al., 2013; Lange, 
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Abstract
Aim: Evaluate for differences in demographic and clinical characteristics and subjec-
tive and objective measures of cognitive function (CF) between younger older adults 
(YOA, 60– 69 years) and older adults (OA, ≥70 years).
Design: Cross- sectional.
Methods: Older oncology patients (n = 139) completed subjective (Attentional 
Function Index, European Organization for the Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC) CF scale) and objective (Montreal Cognitive 
Assessment, Trail Making Test (TMT) A & B) measures of CF prior to chemotherapy. 
Data were analyzed using parametric and nonparametric tests.
Results: No differences were found between the two groups for any of the subjec-
tive or objective CF measures, except that OA patients had higher TMT B scores. 
Compared with the general population, OAs had significantly higher EORTC CF scores 
and YOAs had significantly worse scores for all of the objective tests. Clinically mean-
ingful difference between group differences was found for the TMT B test.
K E Y W O R D S
cancer, cognitive function, older adult, patient- reported outcomes, performance- based 
outcomes
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Rigal, et al., 2014). While findings regarding differences between 
younger and older oncology patients receiving CTX are inconclusive 
(Bompaire et al., 2017; Wefel et al., 2015), recent evidence suggests 
that compared with age- matched controls, older oncology patients 
undergoing CTX experience a decline in cognitive function (Ahles 
& Root, 2018; Lange, Rigal, et al., 2014). Of particular importance 
to older adults is how a cancer diagnosis and its treatments will in-
fluence their level of cognitive function, as well as how to evaluate 
cognitive function in older adults. This information can be used to 
identify older patients who may be at increased risk for cognitive 
deficits.
2  |  BACKGROUND
While findings regarding the correlations between subjective and 
objective measures of CRCI are inconsistent (Wefel et al., 2015) and 
most of these studies have not included older adults (Hutchinson 
et al., 2012), most investigators suggest that to obtain a complete 
picture of cognitive function, both types of measures are needed 
(Hutchinson et al., 2012). Two common self- report measures of CRCI 
are the Attentional Function Index (AFI) (Cimprich et al., 2011) and 
the cognitive function scale of the European Organization for the 
Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ- C30) (Aaronson et al., 1993). While the AFI assesses 
attention and executive function, the EORTC cognitive function 
scale assesses memory and concentration.
In terms of objective measures, the Mini- Mental State 
Examination (MMSE) is one of the most common cognitive screening 
measures that is recommended as part of a Comprehensive Geriatric 
Assessment (CGA) (Hernandez Torres & Hsu, 2017). However, the 
MMSE does not have the sensitivity to detect mild cognitive impair-
ment in older oncology patients (Kurita et al., 2018). Findings from 
several studies suggest that the Montreal Cognitive Assessment 
(MoCA) (Nasreddine et al., 2005) is a more sensitive measure 
to detect these subtle changes (Olson et al., 2011; Pendlebury 
et al., 2010; Zadikoff et al., 2008). In fact, the Canadian Consortium 
on Neurodegeneration in Aging recommended that the MoCA and 
Trail Making Test (TMT) A & B (Tombaugh, 2004) be used as a min-
imum set of measures to evaluate cognitive function in older adults 
(Montero- Odasso et al., 2019).
In terms of studies that used both subjective and objec-
tive measures to evaluate CRCI in older patients (Lange, Giffard, 
et al., 2014; Lange et al., 2016, 2019; Mandelblatt et al., 2014), all 
of them evaluated patients with breast cancer. In the first study, 
which compared older patients to age- matched healthy controls, 
prior to the administration of CTX (Lange, Giffard, et al., 2014), 41% 
of the patients had cognitive deficits based on a battery of neuro-
psychological tests (i.e. episodic memory, working memory, pro-
cessing speed and executive function). Of note, while the patients 
reported better scores on the Functional Assessment of Cancer 
Therapy- cognitive scale (FACT- Cog) than healthy controls, the 
majority of the objective measures did not correlate with the sub-
jective measures. In a follow- up study from this research team, that 
evaluated for changes in cognitive function from before to after 
the completion of adjuvant therapy (Lange et al., 2016), compared 
with the healthy controls, 49% of the older patients with breast 
cancer had a decline in cognitive function based on the objective 
measures. Of these women, 12% had cognitive impairment before 
adjuvant treatment that increased after treatment and 64% of 
them developed impairment after treatment. In addition, patients 
who were ≥75 years of age were at the highest risk for cognitive 
decline at the end of treatment. Again, no significant correlations 
were found between the majority of the subjective and objective 
measures. In a third report from this research group that included 
a post hoc secondary analysis of previously published data (Lange 
et al., 2019), inter- individual variability in the change trajectories of 
the objective measures of cognitive function was evaluated. Five 
change patterns were identified and named no decline, normal 
aging, nonpathologic decline, accelerated cognitive decline and no 
pretreatment cognitive impairment followed by the development 
of cognitive impairment.
In another study of 164 patients with breast cancer who were 
≥60 years of age (Mandelblatt et al., 2014), cognitive function was 
evaluated using the FACT- Cog and a battery of neuropsychological 
tests, prior to the initiation of CTX. Compared with healthy controls 
(n = 182), no differences were found in any of the subjective or ob-
jective measures. However, while not related to being a patient or 
a healthy control, older age increased the odds of having cognitive 
impairment.
While the reports from these two samples of older women 
with breast cancer provide interesting results (Lange, Giffard, 
et al., 2014; Lange et al., 2016, 2019; Mandelblatt et al., 2014), 
they suggest significant inter- individual variability in older adults 
responses to CTX. In addition, only patients with breast cancer 
were evaluated and potential changes in CRCI with increasing age 
were not reported. Given that the population of older adults is 
expected to reach 2.1 billion by 2050 (Jacobsen et al., 1999); that 
nearly two- thirds of all cancers will be diagnosed in individuals 
over 60 years of age (Siegel et al., 2019); and the paucity of re-
search on CRCI in older adults, the purposes of this study, in a 
sample of older patients with gynecological and colorectal cancer 
(n = 139) whose cognitive function was measured prior to the initi-
ation of CTX, using both subjective and objective measures, were 
to: evaluate for differences in demographic and clinical character-
istics between younger older adults (YOA, 60– 69 years of age) and 
older adults (OA, ≥70 years of age); identify differences in subjec-
tive and objective measures of cognitive function between YOA 
and OA; compare the scores for both cognitive function measures 
from our sample of YOA and OA with age- matched samples with-
out cancer drawn from the general population (Fossa et al., 2007; 
Thomann et al., 2018; Tombaugh, 2004). In addition, associations 
between the subjective and objective measures of cognitive func-
tion were evaluated.
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3  |  DESIGN
This study has a cross- sectional design.
4  |  METHODS
4.1  |  Patients and settings
Patients were recruited from one community and two university 
hospitals in Norway. The inclusion criteria were as follows: aged 
≥60 years; diagnosis of gynecological or colorectal cancer; sched-
uled to receive primary or adjuvant CTX; had a MoCA score of ≥23 
(Nasreddine et al., 2005) and had a Karnofsky Performance Status 
(KPS) score of ≥60 (Schag et al., 1984). A total of 208 patients were 
approached and 149 consented to participate (71.6% response rate). 
Of these 149 patients, one withdrew and nine were excluded be-
cause they had a MoCA score of <23. For this analysis, 139 patients 
were included as shown in Figure 1.
4.2  |  Instruments
4.2.1  |  Demographic and clinical characteristics
At enrollment, patients completed a demographic questionnaire that 
obtained information on gender, living arrangements, marital status, 
education, weight and height and employment status. In addition, 
they completed the KPS scale that ranged from 40 (disabled; re-
quires special care and assistance) to 100 (normal no complaints; no 
evidence of disease) (Schag et al., 1984) and the Self- Administered 
Comorbidity Questionnaire (SCQ- 16) (Sangha et al., 2003). The SCQ- 
16 includes 16 common medical conditions. Patients evaluated the 
occurrence, treatment and functional impact of each of the comor-
bid conditions. Total SCQ scores can range from 0– 48. The SCQ- 16 
has well- established validity and reliability (Sangha et al., 2003).
Patients reported visual and hearing impairments and the occur-
rence of tinnitus. The occurrence and severity of visual and hearing 
impairments were assessed by two questions adapted from the 15D 
questionnaire (Sintonen, 2001): (i) Do you have problems with vi-
sion/hearing? and (ii) Do you use any aids to read/hear? To assess 
the occurrence of tinnitus, patients were asked whether they were 
bothered by tinnitus (yes/no).
4.2.2  |  Subjective measures of cognitive function
The AFI (Cimprich et al., 2011) and the cognitive function scale from 
the EORTC QLQ- C30 (Aaronson et al., 1993) were the subjective 
measures of cognitive function used in the study.
The 16- item AFI assesses an individual's perceived effectiveness 
in performing daily activities that are supported by attention and 
working memory (Cimprich et al., 2011). The first 12 items assess 
four components of executive functioning (i.e. goal formulation, 
planning, carrying out activities and monitoring effective perfor-
mance). The last four items assess behavioral and affective responses 
associated with a lowered capacity to direct attention (i.e. making 
mistakes, forgetting, irritability and impatience). Each item is rated 
on a 0– 10 scale. Total and subscales scores (i.e. effective action, at-
tentional lapses and interpersonal effectiveness) are calculated as 
the means of the items. A higher total AFI score indicates greater 
capacity to direct attention (Cimprich et al., 2011). Total scores are 
grouped into three categories of attentional function (i.e. <5.0 low 
function, 5.0– 7.5 moderate function and >7.5 high function). The AFI 
has well- established validity and reliability (Cimprich et al., 2011). In 
the current study, its Cronbach's α was 0.93.
The EORTC QLQ- C30 consists of five function scales (i.e. physi-
cal, role, cognitive, emotional and social), seven symptom scales (i.e. 
fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss 
and constipation), a financial difficulties scale and an overall health 
and QOL scale (Aaronson et al., 1993). The questionnaire has a 1- 
week time frame and uses a four- point response format (“not at all,” 
“a little,” “quite a bit” and “very much”), with the exception of the 
global health status scale, that is scored on a 1 (very poor) to 7 (ex-
cellent) scale. The raw scores were linearly transformed to a 0– 100 
scale, using the algorithm in the EORTC QLQ- C30 scoring manual. 
Higher scores indicate a better level of function and QOL. For the 
symptom scales, higher scores indicate more severe symptoms. The 
cognitive function scale was used in these analyses.
F I G U R E  1  Flow chart of patient enrollment. Abbreviation: 
MoCA, Montreal Cognitive Assessment
Patients invited
n = 208 
Non responders
n = 59 (28%)
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4.2.3  |  Objective measures of cognitive function
The MoCA and the TMT were the objective measures of cognitive 
function used in this study.
The MoCA is a brief screening tool designed to detect mild 
forms of cognitive impairment (Nasreddine et al., 2005). It eval-
uates six cognitive domains: memory, visuospatial abilities, ex-
ecutive functioning, attention and concentration, language and 
orientation (Nasreddine et al., 2005). The short- term memory 
recall task involves recalling five words after 5 min. Visuospatial 
abilities are assessed by having the patient draw a clock and copy a 
three- dimensional cube. Multiple aspects of executive function are 
assessed using a portion of the TMT, a phonemic fluency task and 
a two- item verbal abstraction task. Attention, concentration and 
working memory are evaluated using a sustained attention task, 
a serial subtraction task and a digit's forward and backward task. 
Language is assessed using a three- item confrontation naming task 
with low- familiarity animals (i.e. lion, camel and rhinoceros), the 
repetition of two syntactically complex sentences and the afore-
mentioned fluency task. Finally, orientation to time and place is 
evaluated. If an individual's education is ≤12 years, 1 point is added 
to the total score to achieve a maximum score of 30 (Nasreddine 
et al., 2005). Scores of ≤25 indicate the presence of cognitive im-
pairment (Nasreddine et al., 2005). The MoCA has good psychomet-
ric properties, is sensitive to change over time (Freitas et al., 2012) 
and was used in several studies of older oncology patients (Carlson 
et al., 2018; Edwards et al., 2018; Loh et al., 2017).
The TMT consists of two timed tasks. TMT A provides informa-
tion on difficulties with visual search, visually focused attention and 
psychomotor speed (Luck et al., 2018). TMT B provides information 
on difficulties with executive function (i.e. mental flexibility, includ-
ing task switching, shared attention, working memory, simultaneous 
capacity and planning) (Luck et al., 2018; Tombaugh, 2004). TMT A 
requires an individual to draw lines sequentially connecting 25 en-
circled numbers in order as quickly as possible. Task requirements 
are similar for TMT B except that the person must alternate between 
13 numbers and 13 letters (e.g. 1, A, 2, B, 3, C, …13, L). The score 
for each part is the amount of time required to complete each task 
(Tombaugh, 2004). The TMTs A & B do not have established cut- 
off scores (Luck et al., 2018; Tombaugh, 2004). The TMT is a valid 
measure to assess cognitive function in older patients (Reitan, 1958; 
Tombaugh, 2004) and was used in several studies of older oncology 
patients (Hlubocky et al., 2018; Khan et al., 2019; Weerink et al., 2018).
4.3  |  Study procedures
Oncologists or nurses approached patients prior to the initiation of 
CTX to assess their interest in study participation. Then, patients 
were introduced to the research staff who explained the study, ob-
tained written informed consent and scheduled an appointment to 
perform the measures. The study questionnaires, MoCA and TMT A 
& B were administered in the clinic or in the patient's home before, 
the same day or immediately after the first infusion of CTX. The ad-
ministration of the MoCA and TMT A & B took approximately 15 min. 
Reliability testing for all of the study measures was done on an annual 
basis with all of the research staff. An inter- rater reliability of >90 
was achieved for all of the study measures. Research staff reviewed 
patients’ medical records for disease and treatment information.
4.4  |  Statistical analysis
Data were analyzed using the Statistical Package for the Social 
Sciences version 26 (SPSS, IBM Corporation). While no clear age 
cut- off or definition of an older cancer patient exists, consistent with 
the guidelines from the International Society of Geriatric Oncology 
(Extermann et al., 2005), in this study, older was defined as a person 
of ≥70 years of age. Differences between the two older age groups in 
demographic and clinical characteristics and cognitive function were 
evaluated using independent sample t tests and Chi- square analyses.
For each of the older age groups, one- sample t tests were 
used to compare the oncology patients’ scores on the EORTC 
QLQ- C30 cognitive scale with scores for women from the gen-
eral Norwegian population (YOA = ≥60 years to 70 years and 
OA = ≥70 years to 80 years) (Fossa et al., 2007). For the MoCA, 
patients’ scores were compared with the general German popula-
tion (YOA = ≥65 years to 70 years and OA = ≥75 years to 80 years) 
(Thomann et al., 2018). TMT A & B scores were compared with 
normative data from community- dwelling individuals in Canada 
(YOA = ≥65 years to 70 years and OA = ≥75 years to 80 years) 
(Tombaugh, 2004). The female scores for the EORTC QLQ- C30 
were used as the reference values because the majority of older 
adults in our sample were female (Fossa et al., 2007). No general 
population scores are available for the AFI.
To evaluate for clinically meaningful differences in subjective 
and objective measures of cognitive function between the pa-
tients and individuals drawn from the general population, effect 
size calculations were done (i.e. Cohen's d) and were evaluated 
with cut- offs for small (from 0.2– 0.5), medium (from 0.5– 0.8) 
and large (>0.8) effects (Cohen, 2013). Associations between the 
subjective and objective measures of cognitive function for the 
total sample were done using Pearson product- moment correla-
tion coefficients. A p- value of <.05 was considered statistically 
significant. The STROBE Statement – Checklist for cross- sectional 
studies was used.
5  |  RESULTS
5.1  |  Differences in demographic and clinical 
characteristics
Of the 139 patients, 49.6% were YOA with a mean age of 65.6 
(SD = 3.0) years and 50.4% were OA with a mean age 75.3 (SD = 4.9) 
years (Table 1). Overall, the sample was predominately female 
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(93.5%), married or partnered (62.9%), and 37% had a college degree. 
Except for age, employment status and the occurrence of high blood 
pressure, no differences were found in any of the demographic and 
clinical characteristics between the two age groups. Compared with 
the YOA, OA were less likely to be employed (i.e. 32.8% versus 1.5%, 
p < .001).
In terms of clinical characteristics, the total sample had a 
body mass index (BMI) of 25.8 (SD = 6.0), had a KPS score of 86.7 
(SD = 10.9) and were 1.3 (SD = 3.6) years from their cancer diag-
nosis. Of the total sample, 87.1% had a diagnosis of gynecological 
cancer, 54.0% had had surgery just prior to CTX, and 33.1% were 
being treated for recurrent disease. In addition, these patients had 
1.9 (SD = 1.8) comorbidities and had an SCQ score of 3.7 (SD = 4.0). 
In terms of high blood pressure, compared with the YOA group 
(24.1%), patients in the OA group (45.5%, p = .015) had a higher 
occurrence rate.
5.2  |  Differences in subjective and objective 
measures of cognitive function
No differences were found between the two age groups, for 
any of the subjective measures of cognitive function (Table 2). 
However, when each of the age groups’ EORTC cognitive function 
scores were compared with normative data from the Norwegian 
general population, the OA group had a significantly higher 
score (i.e. better cognitive function) than the general population 
(Figure 2a).
In terms of the objective measures of cognitive function 
(Table 2), no differences were found between the two age groups 
on the MoCA (Figure 2b) and TMT A (Figure 2c) scores. However, 
the OA patients had worse TMT B scores than the YOA patients 
(Figure 2d). Compared with the general population (Thomann 
et al., 2018; Tombaugh, 2004), YOA patients had significantly 
worse scores for all of the objective tests of cognitive function 
(Figure 2b– d).
5.3  |  Clinically meaningful differences 
in subjective and objective measure of 
cognitive function
As shown in Table 3, when effect size calculations were done to 
evaluate for clinically meaningful differences in the subjective and 
objective measures of cognitive function, between the YOA group 
and the general population, effect sizes ranged from −0.15 for the 
EORTC cognitive function scale to 1.27 (i.e. large effect size) for the 
TMT B score. When similar calculations were done between the OA 
group and the general population, effect sizes ranged from −0.06 
for the TMT A score to 0.61 (i.e. medium effect size) for the EORTC 
cognitive function scale.
5.4  |  Associations between subjective and 
objective measures of cognitive function
As shown in Table 4, significant correlations between the subjec-
tive and objective measures ranged from r = .21 for the MoCA total 
score versus the EORTC cognitive function score (p = .018) to r = .28 
for the MoCA total score versus the AFI total score (p < .002). No 
significant correlations were found between either the EORTC cog-
nitive function score or the AFI total score and TMT A.
6  |  DISCUSSION
This study is the first to evaluate for age- related differences in both 
subjective and objective measures of cognitive function in two 
groups of older oncology patients prior to the initiation of CTX. 
Using valid and reliable subjective (i.e. EORTC cognitive function, 
AFI) and objective (i.e. MoCA, TMT A & B) measures of cognitive 
function, except for the TMT B, no differences were found between 
the two age groups, for any of these measures.
In terms of the TMT B, our mean score for the total sample 
(115.9) is consistent with a previous study of older women with 
breast cancer prior to therapy (111.4) (Lange, Giffard, et al., 2014). 
Of note, compared with the YOA, worse scores on the TMT B for the 
OA group represent not only a statistically significant but a clinically 
meaningful difference (d = 0.44). While no established cut- off scores 
exist for the TMT (Luck et al., 2018; Tombaugh, 2004), the same pat-
tern was found between younger (≥65– 70 years of age) and older 
(≥75– 80 years of age) women (d = 0.57) in a German population- 
based study. (Luck et al., 2018). These findings suggest that inde-
pendent of a cancer diagnosis, TMT B scores can detect age- related 
changes in executive function (Luck et al., 2018; Tombaugh, 2004).
In terms of comparisons with the general population, while no 
differences were found between our sample of OA and the gen-
eral population, our YOA had worse scores on all of the objective 
measures. Of note, for the TMT B, this difference was quite large 
(d = 1.27). Given that executive function requires the integration of 
many domains of cognitive function (i.e. mental flexibility, including 
task switching, shared attention, working memory, simultaneous 
capacity and planning) and is critical for adaptive responses to the 
changing demands of the environment (Scherling & Smith, 2013; 
Utne et al., 2018), several explanations for the worse TMT B scores 
in our YOA are plausible. First, given that our YOA were more likely 
to be employed, they may have been experiencing higher levels 
of stress associated with work demands and changes in roles and 
responsibilities at work as a result of cancer treatment (Greidanus 
et al., 2018). In addition, several studies of oncology patients found 
that younger patients reported higher levels of general and cancer- 
specific stress (Langford et al., 2020; Thomas et al., 2010) and that 
higher levels of stress were associated with decrements in cogni-
tive function (Atallah et al., 2020). As noted in one review (Ahles & 
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TA B L E  1  Differences in demographic and clinical characteristics between Younger Older Adults (YOA) and Older Adults (OA)
Characteristics
Total (n = 139)
YOA (<70) 49.6% 
(n = 69)
OA (≥70) 50.4% 
(n = 70)
StatisticsMean (SD) Mean (SD) Mean (SD)
Age (years) 70.5 (6.4) 65.6 (3.0) 75.3 (4.9) t = −14.13; p < .001
Karnofsky Performance Status score 86.7 (10.9) 86.0 (10.4) 87.2 (11.4) t = −0.61; p = .546
Body mass index (kg/m2) 25.8 (6.0) 25.1 (4.9) 26.6 (6.8) t = −1.53; p = .129
Number of comorbidities 1.9 (1.8) 1.7 (1.6) 2.1 (1.9) t = −1.30; p = .195
Self- administered Comorbidity Questionnaire score 3.7 (4.0) 3.2 (3.4) 4.1 (4.4) t = −1.27; p = .208
Time since cancer diagnosis (years) 1.3 (3.6) 1.7 (4.3) 1.0 (2.7) t = 1.22; p = .225
Hemoglobin (g/dl) 12.6 (1.7) 12.4 (1.7) 12.7 (1.6) t = −1.15; p = .253
% (n) % (n) % (n)
Gender
Females 93.5 (130) 91.3 (63) 95.7 (67) FE; p = .326
Males 6.5 (9) 8.7 (6) 4.3 (3)
Married or partnered (% yes) 62.9 (83) 59.4 (38) 66.2 (45) FE; p = .473
Lives alone (% yes) 34.4 (45) 35.9 (23) 32.8 (22) x2 = 1.25; p = .536
Currently employed (% yes) 16.5 (21) 32.8 (20) 1.5 (1) FE; p < .001
Education
Primary school 16.0 (19) 12.5 (7) 19.0 (12) x2 = 0.09; p = .607
High school 47.1 (56) 50.0 (28) 44.4 (28)
College 37.0 (44) 37.5 (21) 36.5 (23)
Vision deficit (% yes) 10.4 (12) 9.8 (5) 10.9 (7) FE; p = 1.000
Aids for reading (% yes) (n = 85) 76.5 (65) 82.1 (32) 71.7 (33) FE; p = .312
Hearing deficit (% yes) 14.8 (18) 10.7 (6) 18.2 (12) FE; p = .310
Aids for hearing (% yes) (n = 75) 12.0 (9) 5.9 (2) 17.1(7) FE; p = .171
Tinnitus (% yes) 18.4 (23) 19.0 (11) 17.9 (12) FE; p = 1.000
Specific comorbidities (% yes)
Heart disease 13.2 (16) 10.3 (6) 15.9 (10) FE; p = .429
High blood pressure 35.5 (44) 24.1 (14) 45.5 (30) FE; p = .015
Lung disease 10.7 (13) 6.9 (4) 14.3 (9) FE; p = .245
Diabetes 7.4 (9) 5.2 (3) 9.4 (6) FE; p = .496
Ulcer or stomach disease 7.4 (9) 3.4 (2) 10.9 (7) FE; p = .168
Bowel disease 9.9 (12) 10.5 (6) 9.4 (6) FE; p = 1.000
Kidney disease 1.7 (2) 1.8 (1) 1.6 (1) FE; p = 1.000
Liver disease 1.7 (2) 0.0 (0) 3.1 (2) FE; p = .498
Anemia/ blood disease 3.4 (4) 0.0 (0) 6.6 (4) FE; p = .120
Headache 8.5 (10) 3.6 (2) 12.9 (8) FE; p = .099
Depression 10.1 (12) 12.3 (7) 8.1 (5) FE; p = .548
Osteoarthritis 41.0 (50) 38.6 (22) 43.1 (28) FE; p = .713
Back pain 32.5 (38) 35.7 (20) 29.5 (18) FE; p = .555
Rheumatoid arthritis 3.4 (4) 1.8 (1) 4.8 (3) FE; p = .621
Disease in connective- tissue 6.8 (8) 10.7 (6) 3.3 (2) FE; p = .150
Skin disease 6.7 (8) 9.1 (5) 4.7 (3) FE; p = .469
Cancer diagnosis
Gynecological 87.8 (122) 84.1 (58) 91.4 (64) FE; p = .206
Colorectal 12.2 (17) 15.9 (11) 8.6 (6)
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Root, 2018), age and stress likely interact to contribute to changes 
in cognitive function in oncology patients. Future studies need to 
include an assessment of general and cancer- specific stress to exam-
ine these inter- relationships.
While no differences were found in EORTC cognitive function 
scores between GP (81.3) and YOA, OA in our study had signifi-
cantly higher scores (89.4; d = 0.61). Our finding is consistent with 
a study of older patients with breast cancer that found that com-
pared with healthy controls the patients reported fewer cognitive 
complaints prior to adjuvant treatment (Lange, Giffard, et al., 2014). 
One possible explanation is that YOAs are more aware of or are 
more likely to report cognitive problems (Magnuson et al., 2019). 
However, it is possible that the two- item EORTC cognitive function 
scale (i.e. concentration and memory) is not sensitive enough to de-
tect subtle changes.
In older adults, impairments in both cognition and mobility are 
associated with central nervous system pathology, even in the ab-
sence of overt neurological disease (Montero- Odasso et al., 2012). 
Brain areas and networks that are involved in gait control and nav-
igation, including prefrontal cortex and hippocampus, are essential 
Characteristics
Total (n = 139)
YOA (<70) 49.6% 
(n = 69)
OA (≥70) 50.4% 
(n = 70)
StatisticsMean (SD) Mean (SD) Mean (SD)
Surgery prior to chemotherapy (% yes) 54.0 (75) 53.6 (37) 54.3 (38) FE; p = 1.000
Metastasis (% yes) 77.6 (104) 74.6 (50) 80.6 (54) FE; p = .535
Treated for recurrent disease (% yes) 33.1 (46) 39.1 (27) 27.1 (19) FE; p = .152
Type of prior cancer treatment (out of 46 patients)
Surgery (% yes) 90.4 (40) 92.0 (23) 89.5 (17) FE; p = 1.000
Radiation therapy (% yes) 15.9 (7) 7.7 (2) 27.8 (5) FE; p = .103
Chemotherapy (% yes) 90.9 (40) 96.2 (25) 83.3 (15) FE; p = .289
Other cancer treatment (% yes) 31.6 (12) 37.5 (9) 21.4 (3) FE; p = .472
Abbreviations: dl, deciliters; FE, Fisher's Exact; g, grams; kg, kilograms; m2, meters squared; SD, standard deviation.
TA B L E  1  (Continued)
TA B L E  2  Differences in subjective and objective measures of cognitive function between Younger Older Adults (YOA) and Older Adults 
(OA)
Characteristics
Total (n = 139)
YOA (<70) 49.6% 
(n = 69)
OA (≥70) 50.4% 
(n = 70)
StatisticsMean (SD) Mean (SD) Mean (SD)
Subjective measures of cognitive function
EORTC QLQ- C30 Cognitive Function scale 87.1 (16.4) 84.5 (19.2) 89.4 (13.3) t = −1.672, p = .097
AFI effective action subscale 7.4 (1.8) 7.2 (1.7) 7.6 (1.9) t = −1.048, p = .297
AFI attentional lapses subscale 7.4 (2.0) 7.4 (2.0) 7.5 (2.1) t = −0.258, p = .797
AFI interpersonal effectiveness subscale 7.6 (1.6) 7.4 (1.5) 7.8 (1.6) t = −1.626, p = .107
AFI total score 7.4 (1.5) 7.3 (1.4) 7.6 (1.6) t = −1.176, p = .242
Objective measures of cognitive function
MoCA visuospatial/executive 4.3 (0.8) 4.2 (0.8) 4.3 (0.8) t = −0.812, p = .418
MoCA naming 2.9 (0.3) 2.9 (0.2) 2.9 (0.3) t = 0.629, p = .530
MoCA attention 5.4 (0.8) 5.4 (0.9) 5.5 (0.8) t = −1.073, p = .285
MoCA language 2.6 (0.6) 2.7 (0.5) 2.5 (0.7) t = 1.865, p = .064
MoCA abstraction 1.5 (0.6) 1.6 (0.6) 1.4 (0.6) t = 1.663, p = .099
MoCA delayed recall 3.1 (1.3) 3.1 (1.3) 3.1 (1.3) t = −0.056, p = .955
MoCA orientation 6.0 (0.2) 6.0 (0.1) 6.0 (0.2) t = 1.000, p = .319
MoCA total score 26.2 (2.1) 26.2 (2.2) 26.1 (2.0) t = 0.046, p = .963
Trail making test A 50.1 (19.7) 48.2 (21.1) 51.9 (18.3) t = −1.085, p = .280
Trail making test B 115.9 (51.8) 104.7 (49.4) 126.6 (52.1) t = −2.52, p = .013
Abbreviations: AFI, Attentional Function Index; EORTC QLQ- C30, European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire; MoCA, Montreal Cognitive Assessment; OA, older adults; SD, standard deviation; YOA, younger older adults.
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F I G U R E  2  Scores for the total sample and differences in scores for the European Organization for the Research and Treatment of Cancer 
Quality of Life Questionnaire cognitive function scale (a), Montreal Cognitive Assessment (MoCA) scale (b), Trail Making Test A (c) and Trail 
Making Test B between the younger older adults (YOA) and the older adults (OA), as well as between each of the older adult age groups and 
the general population. All values are plotted as mean ± standard deviations
































































































between OA and GP
Subjective measures of cognitive function
EORTC cognitive function scale −0.15 0.61§
Attentional function index n/a n/a
Objective measures of cognitive function
Montreal cognitive assessment −0.18 0.15
Trail making test A (sec) 0.43‡ 0.06
Trail making test B (sec) 1.27§ −0.08
Abbreviations: EORTC, European Organization for the Research and Treatment of Cancer Quality 
of Life Questionnaire; GP, general population; n/a, not available; OA, older adults (≥70 years); sec, 
seconds; YOA, younger older adults (60– 69 years).




TA B L E  3  Evaluation of clinically 
meaningful differences in subjective and 
objective measures of cognitive function 
between the general population and each 
of the two age groups†
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for higher- level cognitive function. Therefore, Montero- Odasso and 
colleagues (Montero- Odasso et al., 2019) recommended that tests 
that capture both cognitive and motor function and cognitive- motor 
interactions be used with older adults. They suggest that these tests 
may be able to detect subtle decline and/or predict adverse out-
comes. They recommended that the TMT A & B be used because it: 
has well- established validity and reliability; is sensitive to changes 
in both cognitive performance and mobility; can be used in both re-
search and practice; is free; and requires no special training to ad-
minister (Montero- Odasso et al., 2019). Our findings would support 
this recommendation for the assessment of both younger and older 
oncology patients.
The use of self- report measures to assess cognitive function is 
as important as an objective evaluation because subjective mea-
sures assess the impact of cognitive impairment on individuals’ 
daily lives and ability to function (Hutchinson et al., 2012). While 
several subjective measures are available, in this study we used 
the AFI and the EORTC cognitive function scale. Based on the cor-
relation coefficient between the two measures (r = .57, p < .001), 
they are evaluating different aspects of cognitive function. While 
no population data are available for the AFI, it should be noted 
that for both groups of older adults, the AFI total score would 
be categorized as a high level of cognitive function. Similarly, the 
EORTC cognitive function scores were relatively high. Future 
studies need to examine the sensitivity and specificity of various 
subjective measures to be able to detect subtle changes in cogni-
tive function in older oncology patients.
Consistent with the previous reports (Ahles & Root, 2018; 
Hutchinson et al., 2012), the correlations between the subjective 
and objective measures of CRCI in this study were low (Table 4). 
While a debate exists on the specific subjective and objective mea-
sures to use to assess CRCI in oncology patients, based on the find-
ings from this study and the comments offered by Savard and Ganz 
(Savard & Ganz, 2016), both types of measures are needed to obtain 
a more complete picture of CRCI. Additional research is warranted 
that examines associations between each of these measures and the 
results of functional imaging studies. This type of examination may 
reveal common and distinct brain regions that are associated with 
subjective and objective measures of CRCI (Sousa et al., 2020).
A number of study limitations need to be acknowledged. First, 
the majority of the sample were women with gynecological cancer. 
Therefore, our findings may not generalize to all oncology patients. 
Second, given that older patients are less likely to enroll in clinical 
studies (Abbasi, 2019), it is possible that our participants represent 
a sample of older oncology patients with higher levels of function. 
This hypothesis is supported by the low level of comorbidities in 
this sample. Unfortunately, information on the patients who de-
clined participation is not available because of the restrictions on 
data collection imposed by the Regional Committee for Medical 
and Research Ethics. While the overall sample size was relatively 
large, the two age groups were relatively small. Therefore, findings 
from this study should be replicated in a larger sample. Longitudinal 
studies are needed to evaluate for inter- individual differences in 
cognitive function in older oncology patients and determine which 
demographic, clinical and symptom characteristics are associated 
with changes in cognitive function over time.
7  |  CONCLUSIONS
Subjective and objective measures of cognitive function evaluate 
different aspects of cognitive function in older oncology patients. 
Trail Making Test B may be a useful screening measure of cognitive 
function in older patients.
8  |  RELE VANCE TO CLINIC AL PR AC TICE
Nurses can use these findings to evaluate older oncology patients’ 
cognitive function prior to treatment. Clinicians need to use both 
Measures
MoCA Total 
Score† TMT A† TMT B†
AFI Total 
Score‡
TMT A† r −.11
p .199
TMT B† r −.23 .43
p .006 <.001
AFI Total Score‡ r .28 −.08 −.22
p .002 .418 .013
EORTC QLQ- C30 Cognitive Function‡ r .21 −.02 −.25 .57
p .018 .837 .006 <.001
Abbreviations: AFI, Attentional Function Index; EORTC QLQ- C30, European Organization for 
the Research and Treatment of Cancer Quality of Life Questionnaire; MoCA, Montreal Cognitive 
Assessment; TMT A and B, Trail Making Test A and B.
†Objective measures of cognitive function.
‡Subjective measures of cognitive function.
TA B L E  4  Correlations between 
subjective and objective measures of 
cognitive function
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subjective and objective measures of cognitive function with older 
oncology patients because they evaluate different aspects of cogni-
tive function. This approach would allow clinicians to obtain a more 
complete picture of CRCI. The self- reported measures can be used 
to assess the impact of CRCI on individual patient's daily lives and 
ability to function. Nurses can use this information to identify older 
patients who may be at increased risk for CRCI and warrant ongoing 
monitoring.
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